Search

• ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor

  Media

  Data, along with results from a phase I study, are the first public presentation of VH4524184.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-premieres-early-data-showing-antiviral-activity-against-integrase-resistance-from-its-investigational-third-generation-integrase-inhibitor/

  First published: 23 July 2024

• Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study

  Media

  GSK announced results from Phase 2a study evaluating antiviral activity of INI, S/GSK1349572, results presented at IAS Conference.

  https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1349572-the-only-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-2-study/

  First published: 20 July 2009

• Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects

  Media

  GSK announced results from Phase 1-2a study evaluating PK, safety and activity of its INI S/GSK1265744 in healthy HIV-infected patients.

  https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1265744-a-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-1-2a-study-in-healthy-and-hiv-infected-subjects/

  First published: 13 September 2009

• ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

  Media

  Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-n6ls/

  First published: 25 October 2022

• ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

  Media

  Maturation inhibitors are a class of antiretroviral medicines that target the late stage of the HIV viral life cycle.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/

  First published: 09 March 2021

• GSK receives marketing authorisation from the European Commission for additional Revolade™

  Media

  GSK announced that the EC has granted Revolade™ as a treatment for thrombocytopenia in adult patients with chronic hepatitis C infection.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/

  First published: 24 September 2013

• The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

  Media

  The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic

  https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/

  First published: 28 January 2009

• GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection

  Media

  GSK announced a positive opinion from EMA's CHMP recommending marketing authorisation for Revolade™ (eltrombopag).

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/

  First published: 26 July 2013

• 

  Unlocking the power of the immune system to get ahead of hepatitis B

  Behind the science magazine

  GSK’s innovation team have developed a longer-lasting, more effective treatment for this global health problem

  https://www.gsk.com/en-gb/behind-the-science-magazine/unlocking-the-power-of-the-immune-system-to-get-ahead-of-hepatitis-b/

  First published: 22 June 2022

• 

  Tony Wood

  Company

  Tony was appointed Chief Scientific Officer designate on 19 January 2022 and became Chief Scientific Officer on 1 August 2022.

  https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/tony-wood/

  First published: 12 July 2024